Form 8-K - Current report:
SEC Accession No. 0000950170-25-063167
Filing Date
2025-05-05
Accepted
2025-05-05 08:00:09
Documents
12
Period of Report
2025-05-02
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20250502.htm   iXBRL 8-K 64932
2 EX-99.1 ubx-ex99_1.htm EX-99.1 38366
  Complete submission text file 0000950170-25-063167.txt   227132

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20250502.xsd EX-101.SCH 25006
14 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20250502_htm.xml XML 4539
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 25910953
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)